NDC 72934-1016

BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.05%

Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.05%

BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.05% is a Topical Gel in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida Llc. The primary component is Benzoyl Peroxide; Clindamycin Phosphate; Tretinoin; Niacinamide; Spironolactone.

Product ID72934-1016_87ed3aff-1a1f-c070-e053-2a95a90af490
NDC72934-1016
Product TypeHuman Prescription Drug
Proprietary NameBENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.05%
Generic NameBenzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2% / Tretinoin 0.05%
Dosage FormGel
Route of AdministrationTOPICAL
Marketing Start Date2019-05-03
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida LLC
Substance NameBENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; TRETINOIN; NIACINAMIDE; SPIRONOLACTONE
Active Ingredient Strength5 g/100g; g/100g; g/100g; g/100g; g/100g
Pharm ClassesDecreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [CS],Retinoid [EPC],Retinoids [CS],Aldosterone Antagonist [EPC],Aldosterone Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-1016-2

30 g in 1 BOTTLE, PUMP (72934-1016-2)
Marketing Start Date2019-05-03
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-1016-2 [72934101602]

BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.05% GEL
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-03

Drug Details

Active Ingredients

IngredientStrength
BENZOYL PEROXIDE5 g/100g

Pharmacological Class

  • Decreased Sebaceous Gland Activity [PE]
  • Lincosamide Antibacterial [EPC]
  • Lincosamides [CS]
  • Retinoid [EPC]
  • Retinoids [CS]
  • Aldosterone Antagonist [EPC]
  • Aldosterone Antagonists [MoA]
  • Decreased Sebaceous Gland Activity [PE]
  • Lincosamide Antibacterial [EPC]
  • Lincosamides [CS]
  • Retinoid [EPC]
  • Retinoids [CS]
  • Aldosterone Antagonist [EPC]
  • Aldosterone Antagonists [MoA]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.